L. Phan

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.

C. Tournigand, K. Bensalah, J. Bernhard, 2022, The Lancet. Oncology.

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

J. Pouchot, E. Tartour, J. Medioni, 2023, Oncoimmunology.

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

S. Oudard, G. Gravis, N. Houédé, 2022, International journal of cancer.

Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.

C. Tournigand, C. Sautès-Fridman, W. Fridman, 2023, Journal of Clinical Oncology.

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

A. Ravaud, S. Oudard, P. Barthélémy, 2020, Cancers.

Comparative E ffi cacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

A. Ravaud, P. Barthélémy, Y. Vano, 2020 .

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

A. Thiery-Vuillemin, E. Voog, C. Helissey, 2023, JAMA oncology.